April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Predictive Factors Of Chorioretinal Atrophy Progression After Anti-VEGF Therapy For Myopic Choroidal Neovascularization
Author Affiliations & Notes
  • Akio Oishi
    Ophthalmology, Kobe City General Hospital, Kobe, Japan
  • Michiko Mandai
    Ophthalmology, Kobe City General Hospital, Kobe, Japan
  • Mikiko Kimakura
    Ophthalmology, Kobe City General Hospital, Kobe, Japan
  • Akihiro Nishida
    Ophthalmology, Kobe City General Hospital, Kobe, Japan
  • Yasuo Kurimoto
    Ophthalmology, Kobe City General Hospital, Kobe, Japan
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2721. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Akio Oishi, Michiko Mandai, Mikiko Kimakura, Akihiro Nishida, Yasuo Kurimoto; Predictive Factors Of Chorioretinal Atrophy Progression After Anti-VEGF Therapy For Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2721.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To explore the predictive factors of development or enlargement of chorioretinal atrophy after anti-VEGF therapy for myopic choroidal neovascularization (mCNV).

Methods: : We investigated 35 patients with mCNV who underwent intravitreal injection of ranibizumab or bevacizumab and followed up for more than 12 months. Fundus photographs before the treatment and at the final visit were compared and judged if the chorioretinal atrophy developed or enlarged. A multivariate analysis was performed using stepwise logistic regression analysis to determine the independent predictors of progression of chorioretinal atrophy. The analyzed factors consisted of age, axial length, CNV area, previous photodynamic therapy, preoperative visual acuity (logMAR), number of injections, and the observation period.

Results: : Chorioretinal atrophy developed or enlarged in 9 cases. Among the above factors, only preoperative logMAR was a significant factor of development or enlargement of chorioretinal atrophy (odds ratio, 16.0, 95%CI 1.5-174.1: one unit change of logMAR increases or decreases the risk of chorioretinal atrophy by 16 folds).

Conclusions: : Preoperative poor visual acuity is a risk factor of progression of chorioretinal atrophy in mCNV patients treated with anti-VEGF therapy.

Keywords: choroid: neovascularization • myopia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×